Discovery and development of biomarkers of neurological disease

Drug Discovery Today

Volumn 10, Issue 5, 2005, Pages 326-334

  Dunckley, Travis ^a   Coon, Keith D ^a   Stephan, Dietrich A ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE MARKER; GENE MAPPING; GENE MUTATION; GENE OVEREXPRESSION; GENOMICS; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; NEUROLOGIC DISEASE; NONHUMAN; PROTEOMICS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SIGNAL TRANSDUCTION; VALIDATION PROCESS;

ANIMALS; BIOLOGICAL MARKERS; GENOMICS; HUMANS; NERVOUS SYSTEM DISEASES; PROTEOMICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 14644442276     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03353-7     Document Type: Review

References (83)

1. Gershon E.S., Goldin L.R. Clinical methods in psychiatric genetics. I. Robustness of genetic marker investigative strategies. Acta Psychiatr. Scand. 74:1986;113-118
2. Leboyer M., et al. Psychiatric genetics: search for phenotypes. Trends Neurosci. 21:1998;102-105
3. Hulette C.M., et al. Evaluation of cerebral biopsies for the diagnosis of dementia. Arch. Neurol. 49:1992;28-31
4. Perry E.K., et al. The influence of agonal status on some neurochemical activities of postmortem human brain tissue. Neurosci. Lett. 29:1982;303-307
5. Ferrer I., Blanco R. N-myc and c-myc expression in Alzheimer disease, Huntington disease and Parkinson disease. Brain Res. Mol. Brain Res. 77:2000;270-276
6. Hulette C.M., et al. Rapid brain autopsy. The Joseph and Kathleen Bryan Alzheimer's Disease Research Center experience. Arch. Pathol. Lab. Med. 121:1997;615-618
7. Haroutunian V., Davis K.L. Issues and perspectives on brain tissue banking. Curr. Psychiatry Rep. 4:2002;233-234
8. Riaz S., Nowack W.J. Diagnostic problems in multiple sclerosis: overreliance on neuroimaging. South. Med. J. 91:1998;270-272
9. Levin N., et al. Patterns of misdiagnosis of multiple sclerosis. Isr. Med. Assoc. J. 5:2003;489-490
10. Poewe W., Wenning G. The differential diagnosis of Parkinson's disease. Eur. J. Neurol. 9:(Suppl. 3):2002;23-30
11. Mangino M., Middlemiss C. Alzheimer's disease: preventing and recognizing a misdiagnosis. Nurse Pract. 22:1997;58-59. 63-68, 70 passim
12. McKhann G., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944
13. American Psychiatric Association. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV. 1994;American Psychiatric Association, Washington, DC
14. Chui H., Young Lee A. Clinical criteria for various dementia subtypes: Alzheimer's disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). Qizilbash N.,, et al. Blackwell Science. 2001
15. Petrovitch H., et al. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology. 57:2001;226-234
16. Gearing M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology. 45:1995;461-466
17. Barker W.W., et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis. Assoc. Disord. 16:2002;203-212
18. Mastaglia F.L., et al. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. Mov. Disord. 18:2003;81-86
19. Hutton M., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 393:1998;702-705
20. Iseki E., et al. Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol. (Berl.). 105:2003;265-270
21. Sanchez M.P., et al. Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation. J. Alzheimers Dis. 4:2002;399-404
22. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. (Berl.). 82:1991;239-259
23. Weiner A. Soaking up RNAi. Mol. Cell. 12:2003;535-536
24. Luo W.J., et al. PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. J. Biol. Chem. 278:2003;7850-7854
25. Hassani, Z. et al. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J. Gene Med. (in press)
26. Lue L.F., Walker D.G. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. J. Neurosci. Res. 70:2002;599-610
27. Takahashi K., et al. Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. J. Clin. Invest. 110:2002;1791-1799
28. Williams T., et al. Diet-induced obesity and cardiovascular regulation in C57BL/6J mice. Clin. Exp. Pharmacol. Physiol. 30:2003;769-778
29. Davies E.L., et al. Functional enhancement of electrofusion-derived BRIN-BD11 insulin-secreting cells after implantation into diabetic mice. Int. J. Exp. Diabetes Res. 2:2001;29-36
30. Lesniewski L.A., et al. Mechanisms of force loss in diabetic mouse skeletal muscle. Muscle Nerve. 28:2003;493-500
31. Taki S. Type I interferons and autoimmunity: lessons from the clinic and from IRF-2-deficient mice. Cytokine Growth Factor Rev. 13:2002;379-391
32. Ishimaru N., et al. Development of autoimmune exocrinopathy resembling Sjogren's syndrome in estrogen-deficient mice of healthy background. Am. J. Pathol. 163:2003;1481-1490
33. Jackson E.L., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15:2001;3243-3248
34. Li X., et al. Optically imageable metastatic model of human breast cancer. Clin. Exp. Metastasis. 19:2002;347-350
35. Cox C., et al. Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch. Otolaryngol. Head Neck Surg. 129:2003;781-785
36. Garcia-Castro J., et al. Purging of leukemia-contaminated bone marrow grafts using suicide adenoviral vectors: an in vivo murine experimental model. Gene Ther. 10:2003;1328-1335
37. Sfacteria A., et al. Cyclin D1 expression in pre-cancerous and cancerous lesions of the canine mammary gland. J. Comp. Pathol. 128:2003;245-251
38. Link C.D., et al. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol. Aging. 24:2003;397-413
39. Finelli A., et al. A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. Mol. Cell. Neurosci. 26:2004;365-375
40. Yamaguchi F., et al. Transgenic mice for the amyloid precursor protein 695 isoform have impaired spatial memory. Neuroreport. 2:1991;781-784
41. Wirak D.O., et al. Deposits of amyloid beta protein in the central nervous system of transgenic mice. Science. 253:1991;323-325
42. Kammesheidt A., et al. Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain. Proc. Natl. Acad. Sci. U. S. A. 89:1992;10857-10861
43. Higgins L.S., et al. Transgenic mouse brain histopathology resembles early Alzheimer's disease. Ann. Neurol. 35:1994;598-607
44. Moran P.M., et al. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 92:1995;5341-5345
45. Lamb B.T., et al. Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice. Nat. Genet. 5:1993;22-30
46. Pearson B.E., Choi T.K. Expression of the human beta-amyloid precursor protein gene from a yeast artificial chromosome in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 90:1993;10578-10582
47. Borchelt D.R., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 17:1996;1005-1013
48. Citron M., et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3:1997;67-72
49. Chui D.H., et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat. Med. 5:1999;560-564
50. Borchelt D.R., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 19:1997;939-945
51. Holcomb L., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:1998;97-100
52. Strazielle C., et al. Regional brain cytochrome oxidase activity in beta-amyloid precursor protein transgenic mice with the Swedish mutation. Neuroscience. 118:2003;1151-1163
53. Oddo S., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 39:2003;409-421
54. Bertelson C.J., et al. Localisation of Xp21 meiotic exchange points in Duchenne muscular dystrophy families. J. Med. Genet. 23:1986;531-537
55. Dobrin S.E., Stephan D.A. Integrating microarrays into disease-gene identification strategies. Expert Rev. Mol. Diagn. 3:2003;375-385
56. Dybkaer K., et al. Molecular diagnosis and outcome prediction in diffuse large B-cell lymphoma and other subtypes of lymphoma. Clin. Lymphoma. 5:2004;19-28
57. Nambiar S., et al. Applications of array technology: melanoma research and diagnosis. Expert Rev. Mol. Diagn. 4:2004;549-557
58. Petty R.D., et al. Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin. Cancer Res. 10:2004;3237-3248
59. Yamada S.I., et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene. 23:2004;5901-5911
60. Hoek K., et al. Expression profiling reveals novel pathways in the transformation of Melanocytes to Melanomas. Cancer Res. 64:2004;5270-5282
61. Li S.R., et al. Differential expression patterns of the insulin-like growth factor 2 gene in human colorectal cancer. Tumour Biol. 25:2004;62-68
62. Woo I.S., et al. Expression of placental growth factor gene in lung cancer. Tumour Biol. 25:2004;1-6
63. Mazzanti C., et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 64:2004;2898-2903
64. Ginsberg S.D., et al. Single-cell gene expression analysis: implications for neurodegenerative and neuropsychiatric disorders. Neurochem. Res. 29:2004;1053-1064
65. Bomprezzi R., et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. 12:2003;2191-2199
66. Rai A.J., Chan D.W. Cancer Proteomics: Serum Diagnostics for Tumor Marker Discovery. Ann. N. Y. Acad. Sci. 1022:2004;286-294
67. Rodland K.D. Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin. Biochem. 37:2004;579-583
68. Davidsson P., et al. Clinical mass spectrometry in neuroscience. Proteomics and peptidomics. Cell. Mol. Biol (Noisy-le-grand). 49:2003;681-688
69. Puchades M., et al. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol. Brain Res. 118:2003;140-146
70. Gygi S.P., et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17:1999;994-999
71. Johnson M.D., et al. Proteome analysis of DNA damage-induced neuronal death using high throughput mass spectrometry. J. Biol. Chem. 279:2004;26685-26697
72. Olsen J.V., et al. HysTag - a novel proteomic quantification tool applied to differential display analysis of membrane proteins from distinct areas of mouse brain. Mol. Cell. Proteomics. 3:2003;82-92
73. Che F.Y., Fricker L.D. Quantitation of neuropeptides in Cpe(fat)/Cpe(fat) mice using differential isotopic tags and mass spectrometry. Anal. Chem. 74:2002;3190-3198
74. Hamler R.L., et al. A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics. 4:2004;562-577
75. Lindon J.C., et al. Metabolomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers. 9:2004;1-31
76. Griffin J.L., et al. Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3. Physiol. Genomics. 16:2004;334-340
77. Ohdoi C., et al. Chemical diagnosis of Lesch-Nyhan syndrome using gas chromatography-mass spectrometry detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 792:2003;123-130
78. Rosenfeld S. New developments in cancer-related computational statistics. Ann. N. Y. Acad. Sci. 1020:2004;22-31
79. Looney S.W. Statistical methods for assessing biomarkers. Methods Mol. Biol. 184:2002;81-109
80. Gieser P., et al. Introduction to microarray experimentation and analysis. Methods Mol. Biol. 184:2002;29-49
81. Lazaridis E.N., Bloom G.C. Statistical contributions to molecular biology. Methods Mol. Biol. 184:2002;1-14
82. Kim S.I., et al. Neuroproteomics: expression profiling of the brain's proteomes in health and disease. Neurochem. Res. 29:2004;1317-1331
83. Freeman W.M., Hemby S.E. Proteomics for protein expression profiling in neuroscience. Neurochem. Res. 29:2004;1065-1081